Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
https://www.prnewswire.com/news-releases/hi-bio-to-present-at-the-61st-european-renal-association-era-congress-302103190.html
https://www.prnewswire.com/news-releases/hi-bio-receives-fda-orphan-drug-designation-for-felzartamab-for-the-treatment-of-antibody-mediated-rejection-amr-in-kidney-transplant-recipients-302095317.html
https://www.prnewswire.com/news-releases/hi-bio-announces-95-million-series-b-financing-to-advance-targeted-therapies-for-immune-mediated-diseases-302025700.html
https://www.prnewswire.com/news-releases/hi-bio-announces-felzartamab-granted-breakthrough-therapy-designation-by-us-food-and-drug-administration-for-primary-membranous-nephropathy-pmn-301973164.html
https://www.prnewswire.com/news-releases/hi-bio-initiates-healthy-volunteer-study-of-hib210-for-immune-mediated-diseases-301873618.html
https://www.prnewswire.com/news-releases/hi-bio-receives-fda-orphan-drug-designation-for-felzartamab-for-the-treatment-of-membranous-nephropathy-301834111.html
https://www.prnewswire.com/news-releases/hi-bio-announces-positive-phase-2-data-on-felzartamab-for-the-treatment-of-primary-membranous-nephropathy-301793691.html